홈 > 시장보고서 > 의약품 > 감염질환

시장보고서

상품코드

1321043

인유두종바이러스 백신 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년)

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition

발행일: 2023년 08월 | 리서치사:

TechSci Research | 페이지 정보: 영문 116 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 인유두종바이러스 백신 시장은 2024-2028년의 예측 기간 중 괄목할 만한 성장을 달성할 것으로 예상됩니다.

인유두종바이러스 관련 질환 증가, 세계에서 인유두종바이러스 관련 인식을 높이기 위한 정부 및 민간 기관의 구상이 증가함에 따라 시장 성장을 확장하고 있습니다. 인유두종바이러스 감염은 자궁경부암, 음경암, 생식기암 등 인유두종바이러스 관련 암을 유발하는 가장 흔한 성병입니다. 인유두종바이러스 백신은 특정 유형의 인유두종바이러스로부터 보호하는 예방 접종입니다. 이 백신은 2가지, 4가지 또는 9가지 유형의 인유두종바이러스로부터 보호할 수 있습니다. 시장 성장을 지원하는 요인으로는 치료용 백신 개발을 위한 연구 증가, 다수의 임상시험, 인지도 향상 및 정부 투자, 유두종 바이러스 감염을 줄이기 위한 필요성 증가 등이 있습니다. 세계에서 약 394건의 유두종 바이러스 백신 관련 임상연구가 다양한 개발 단계에 있습니다.

인유두종바이러스 질환 사례 증가

항문, 구인두, 생식기 등 다양한 기관에서 인유두종바이러스 관련 질환이 급증하면서 인유두종바이러스 백신에 대한 수요가 크게 증가하여 시장 성장에 유리한 기회를 창출하고 있습니다. 시장에는 2가, 4가, 비가 등 세 가지 유형의 백신이 있습니다. 이 세 가지 백신은 모두 자궁경부암 환자의 70%를 치료하는 16형과 18형 바이러스 감염을 예방하는 데 매우 효과적입니다. 미국 질병예방통제센터(CDC)에 따르면 미국에서는 인유두종바이러스가 가장 흔한 성병입니다. 외음부 및 질 질환의 70% 이상, 음경 악성 종양의 60%, 항문암과 자궁경부 종양의 90%가 인유두종바이러스에 의해 발생합니다. 또한 여성의 경우 자궁경부암은 9세에서 30세 사이에 매우 흔하게 발생해 HPV 백신의 필요성에 박차를 가하고 있습니다. 예를 들어 세계보건기구(WHO)에 따르면 2017년 자궁경부암으로 인한 여성 사망자 수는 세계에서 2,500,000명을 넘어섰으며, 그 중 85%가 개발도상국에서 발생했습니다.

정부·민간단체별 구상의 증가

지난 수년간 여러 국가의 정부와 민간 단체는 유두종 바이러스에 대한 대중의 인식을 높이기 위해 여러 가지 조치를 취하여 인유두종바이러스 백신 시장의 성장을 가속하고 있습니다. 그 결과, 인유두종바이러스 백신과 관련된 연구개발 활동과 제품 출시가 증가하고 있습니다. 예를 들어 최근 인도에서는 자궁경부암에 대한 최초의 4가 인간유두종바이러스 백신(qHPV)이 출시되었습니다. 또한 프로펙터스 바이오사이언스는 HPV 치료 백신인 GeneVax prime/VesiculoVax를 개발 중입니다. 이 백신은 7종의 인유두종바이러스에 효과가 있는 것으로 알려져 있습니다. 또한 유니세프를 중심으로 한 단체들은 수년간 백신의 수용성을 높이기 위해 노력해 왔습니다. 범미보건기구(PAHO)의 회전기금과 유니세프 공급 부문의 영향으로 다양한 국가에서 보다 저렴한 가격으로 예방접종을 받을 수 있게 되었습니다.

시장 세분화

세계의 인유두종바이러스 백신 시장은 가가, 적응증 질환, 유통 채널, 기업으로 구분됩니다. 가가에 따라 시장은 2가, 4가, 4가, 비가, 기타로 나뉩니다. 적응증별로는 자궁경부암, 항문암, 질암, 음경암, 음경암, 외음부암, 기타로 분류됩니다. 판매 채널별로는 병원/클리닉, 정부/비정부기구, 공공/민간 연합, 기타로 분류됩니다. 국가별로는 미국은 인유두종바이러스 관련 질환의 유병률 증가와 의료 인프라가 잘 갖추어져 있으며, 예측 기간 중 유리한 시장이 될 것으로 예상됩니다.

시장 기업

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson &Johnson, Merck &Co., Inc., AstraZeneca Plc., Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, Bharat Biotech International Limited 등이 시장에서 사업을 운영하는 주요 기업입니다.

사용 가능한 커스터마이제이션

TechSci 리서치는 주어진 시장 데이터를 사용하여 기업의 특정 요구에 따라 맞춤화할 수 있습니다. 보고서에서는 다음과 같은 커스터마이제이션이 가능합니다. :

기업 정보

추가 시장 진출기업(최대 5개사)에 대한 심층 분석 및 프로파일링

Business Overview
Company Snapshot
Products & Services
Financials(As reported)
Recent Developments
SWOT Analysis
- Serum Institute of India Pvt. Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co., Inc.
- AstraZeneca Plc
- Novartis AG
- Inovio Pharmaceuticals, Inc.
- Xenetic Biosciences, Inc.
- Sanofi SA
- Bharat Biotech International Limited

제16장 전략적 제안

KSA 23.08.22

Global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide, are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain types of human papillomavirus. It protects against either two, four, or nine kinds of Human Papillomavirus Virus. The factors supporting the market's growth are the increasing research for the development of therapeutic vaccines, the large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.

Increasing Cases of Human Papillomavirus Diseases

Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth. There are just three types of vaccines in the market: bivalent, tetravalent, and nonvalent. All three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in the United States, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of Human Papillomavirus. Moreover, in women, cervical cancer is very common among those age between 9 to 30, which spurs the need for the HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer was liable for over 2,50,000 deaths of women globally, and 85% of these deaths occurred in developing countries.

Increasing Initiatives by Government & Private Organizations

Over the past few years, governments of different nations and private organizations have been taking several steps to create awareness among the population with regard to papillomavirus among the population, thereby driving the growth of the human papillomavirus vaccine market. This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in the process of developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven Human Papillomavirus kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.

Market Segmentation

Global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is categorized into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of human papillomavirus-related diseases and better healthcare infrastructure in the country.

Market Players

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.

Report Scope

In this report, global human papillomavirus vaccine market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Human Papillomavirus Vaccine Market, By Valence:

Bivalent
Quadrivalent
Nonvalent
Others

Human Papillomavirus Vaccine Market, By Disease Indication:

Cervical Cancer
Anal Cancer
Vaginal Cancer
Penile Cancer
Vulvar Cancer
Others

Human Papillomavirus Vaccine Market, By Distribution Channel:

Hospitals & Clinics
Governmental & Non-Governmental Organizations
Public & Private Alliances
Others

Human Papillomavirus Vaccine Market, By Region:

North America
- United States
- Canada
- Mexico

Europe
- Germany
- France
- United Kingdom
- Spain
- Italy

Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea

South America
- Brazil
- Argentina
- Colombia

Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Human Papillomavirus Vaccine Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. Patent Analysis

7. Global Human Papillomavirus Vaccine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
- 7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
- 7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
- 7.2.4. By Region
- 7.2.5. By Company (2022)
7.3. Market Map
- 7.3.1. By Valence
- 7.3.2. By Disease Indication
- 7.3.3. By Distribution Channel
- 7.3.4. By Region

8. North America Human Papillomavirus Vaccine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Valence
- 8.2.2. By Disease Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Human Papillomavirus Vaccine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Valence
    - 8.3.1.2.2. By Disease Indication
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Valence
    - 8.3.2.2.2. By Disease Indication
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Canada Human Papillomavirus Vaccine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Valence
    - 8.3.3.2.2. By Disease Indication
    - 8.3.3.2.3. By Distribution Channel

9. Europe Human Papillomavirus Vaccine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Valence
- 9.2.2. By Disease Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Europe: Country Analysis
- 9.3.1. France Human Papillomavirus Vaccine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Valence
    - 9.3.1.2.2. By Disease Indication
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Germany Human Papillomavirus Vaccine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Valence
    - 9.3.2.2.2. By Disease Indication
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Valence
    - 9.3.3.2.2. By Disease Indication
    - 9.3.3.2.3. By Distribution Channel
- 9.3.4. Italy Human Papillomavirus Vaccine Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Valence
    - 9.3.4.2.2. By Disease Indication
    - 9.3.4.2.3. By Distribution Channel
- 9.3.5. Spain Human Papillomavirus Vaccine Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Valence
    - 9.3.5.2.2. By Disease Indication
    - 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Valence
- 10.2.2. By Disease Indication
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. Asia-Pacific: Country Analysis
- 10.3.1. China Human Papillomavirus Vaccine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Valence
    - 10.3.1.2.2. By Disease Indication
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. India Human Papillomavirus Vaccine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Valence
    - 10.3.2.2.2. By Disease Indication
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Japan Human Papillomavirus Vaccine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Valence
    - 10.3.3.2.2. By Disease Indication
    - 10.3.3.2.3. By Distribution Channel
- 10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Valence
    - 10.3.4.2.2. By Disease Indication
    - 10.3.4.2.3. By Distribution Channel
- 10.3.5. Australia Human Papillomavirus Vaccine Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Valence
    - 10.3.5.2.2. By Disease Indication
    - 10.3.5.2.3. By Distribution Channel

11. South America Human Papillomavirus Vaccine Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Valence
- 11.2.2. By Disease Indication
- 11.2.3. By Distribution Channel
- 11.2.4. By Country
11.3. South America: Country Analysis
- 11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Valence
    - 11.3.1.2.2. By Disease Indication
    - 11.3.1.2.3. By Distribution Channel
- 11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Valence
    - 11.3.2.2.2. By Disease Indication
    - 11.3.2.2.3. By Distribution Channel
- 11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Valence
    - 11.3.3.2.2. By Disease Indication
    - 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook

12.1. Market Size & Forecast
- 12.1.1. By Value
12.2. Market Share & Forecast
- 12.2.1. By Valence
- 12.2.2. By Disease Indication
- 12.2.3. By Distribution Channel
- 12.2.4. By Country
12.3. MEA: Country Analysis
- 12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
  - 12.3.1.1. Market Size & Forecast
    - 12.3.1.1.1. By Value
  - 12.3.1.2. Market Share & Forecast
    - 12.3.1.2.1. By Valence
    - 12.3.1.2.2. By Disease Indication
    - 12.3.1.2.3. By Distribution Channel
- 12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
  - 12.3.2.1. Market Size & Forecast
    - 12.3.2.1.1. By Value
  - 12.3.2.2. Market Share & Forecast
    - 12.3.2.2.1. By Valence
    - 12.3.2.2.2. By Disease Indication
    - 12.3.2.2.3. By Distribution Channel
- 12.3.3. UAE Human Papillomavirus Vaccine Market Outlook
  - 12.3.3.1. Market Size & Forecast
    - 12.3.3.1.1. By Value
  - 12.3.3.2. Market Share & Forecast
    - 12.3.3.2.1. By Valence
    - 12.3.3.2.2. By Disease Indication
    - 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

13.1. Drivers
13.2. Challenges

14. Market Trends & Developments

14.1. Recent Developments
14.2. Mergers & Acquisitions
14.3. Product Launches

15. Competitive Landscape

15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As reported)
15.5. Recent Developments
15.6. SWOT Analysis
- 15.6.1. Serum Institute of India Pvt. Ltd.
- 15.6.2. GlaxoSmithKline Plc.
- 15.6.3. Johnson & Johnson
- 15.6.4. Merck & Co., Inc.
- 15.6.5. AstraZeneca Plc
- 15.6.6. Novartis AG
- 15.6.7. Inovio Pharmaceuticals, Inc.
- 15.6.8. Xenetic Biosciences, Inc.
- 15.6.9. Sanofi SA
- 15.6.10. Bharat Biotech International Limited

16. Strategic Recommendations

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,385,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 5,500

￦ 7,805,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

US $ 8,000

￦ 11,352,000

※ 부가세 별도

인유두종바이러스 백신 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측(2018-2028년)

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition

인유두종바이러스 질환 사례 증가

정부·민간단체별 구상의 증가

시장 세분화

시장 기업

사용 가능한 커스터마이제이션

기업 정보

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 임상시험 분석

제6장 특허 분석

제7장 세계의 인유두종바이러스 백신 시장 전망

제8장 북미의 인유두종바이러스 백신 시장 전망

제9장 유럽의 인유두종바이러스 백신 시장 전망

제10장 아시아태평양의 인유두종바이러스 백신 시장 전망

제11장 남미의 인유두종바이러스 백신 시장 전망

제12장 중동 및 아프리카의 인유두종바이러스 백신 시장 전망

제13장 시장 역학

제14장 시장 동향과 발전

제15장 경쟁 구도